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choriocarcinoma focus after ovarian non-gestastional
choriocarcinoma: A case report
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Abstract
Introduction.  Choriocarcinoma is a malignant form of
gestational trophoblastic neoplasm (GTN). It is a rare event
but also a curable malignancy. In the majority of instancies
it developes after any gestational event. In some cases it de-
velopes as non-gestational extrauterine malignancy. Progno-
sis of choriocarcinoma is poor when invasion and metasta-
ses appear early and spread fast. This form of choriocarci-
noma can lead to incurable and letal outcome. Case report.
We presented a 20-year-old patient with abdominal and ret-
roperitoneal malignancy – anaplastic carcinoma combined
with choriocarcinoma metastases in. Tumor developed
three months after left adnexectomy which had been done
because of adnexal tumor. Choriocarcinoma was immuno-
histochemicaly confirmed in adnexal masses. Two courses
of chemotherapy, metotrexate + folic acid (MTX+FA)
regimen, were administrated. The initial serum beta human
chorionic gonadotropin level stayed unknown as well as the
last one after the treatment. The patient came from the
other country and was hospitalized because of pelvic and
abdominal pain and palpable abdominal masses in hypo-
gastrium with progressive anemia. The human chorionic
gonadotropin level was 38 mIU/L. Tumor biopsy was done
and choriocarcinoma metastases were immunohistochemi-
caly confirmed with predominant anaplastic carcinoma. Five
day course of MTX + cyclophosphamide regimen was ad-
ministrated and the patient was prepared for operative
treatment. Relaparotomy was perforemed and tumor com-
pletely exceeded. Tumor mass mostly developed retroperi-
tonely and partialy in abdominal cavity infiltrating intestinal
wall with rupture of sigmoid colon. Anaplastic carcinoma,
with large fields of necrosis and bleeding, was confirmed
after histological examination. Immunohistochemical ex-
amination excluded choriocarcinoma in tumor mass. After
20 blood units transfusion, one course of chemotherapy and
tumor excision, the patient left hospital on the 9th postop-
erative day. The patient rejected chemotherapy which was
recommended according to the protocol and died one
month after the operation. Conclusion.  Non-gestational
metastatic choriocarcinoma complicated with another type
of malignancy with early spread of the disease and low re-
sponsiriness to chemotherapy has poor prognosis and leads
to lethal outocome.
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Apstrakt
Uvod. Horiokarcinom je maligni oblik gestacijske trofob-
lastne neoplazme (GTN). Javlja se retko, ali spada u izleÿi-
ve malignitete. U veýini sluÿajeva razvija se nakon trudno-
ýe. U nekim sluÿajevima može se razviti i kao negestacijski
vanmateriÿni malignitet. Prognoza je loša kada se invazija i
metastaze horiokarcinoma pojave rano i ako se brzo šire.
Taj oblik horiokarcinoma može biti neizleÿiv i dovesti do
letalnog ishoda. Prikaz bolesnika. Prikazali smo bolesni-
cu, staru 20 godina, sa abdominalnim i retroperitonealnim
malignitetom – anaplastiÿnim karcinomom sa horiokarci-
nomskim metastazama. Tumor se razvio tri meseca nakon
leve adneksektomije koja je uraĀena zbog adneksalnog tu-
mora. Horiokarcinom je imunohistohemijski potvrĀen iz
adneksalne mase. Date su dve kure hemoterapije metotre-
ksatom i folnom kiselinom. Inicijalna vrednost beta hu-
manog horionskog gonadotropina ostala je nepoznata, kaoStrana 1098 VOJNOSANITETSKI PREGLED Volumen 69, Broj 12
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i poslednja nakon tretmana. Bolesnica je došala iz druge
zemlje i hospitalizovana je zbog bolova u predelu abdo-
mena i male karlice i palpabilne mase u hipogastrijumu,
praýene progresivnom anemijom. Nivo humanog horion-
skog gonadotropina bio je 38 mIU/L. Naÿinjena je biop-
sija tumora i metastaze horiokarcinoma su imunohistohe-
mijski potvrĀene sa predominacijom anaplastiÿnog karci-
noma. Data je petodnevna kura metotreksata i ciklofosfa-
mida i bolesnica je pripremana za operativno leÿenje. Na-
ÿinjena je relaparotomija i tumor je u potpunosti uklonjen.
Tumorska masa se najviše razvijala retroperitonealno, a
delimiÿno i u abdominalnoj duplji infiltrišuýi zid creva sa
rupturom sigmoidnog kolona. Anaplastiÿni karcinom sa
velikim poljima nekroze i krvarenja potvrĀen je nakon hi-
stološkog pregleda. Imunohistohemijskim ispitivanjem is-
kljuÿeno je horiokarcinom u tumorskoj masi. Nakon 20
jedinica transfuzije krvi, jedne kure hemioterapije i ukla-
njanja tumora, bolesnica je napustila bolnicu 9. postopera-
tivnog dana. Odbila je hemoterapiju koja je bila preporu-
ÿena prema protokolu i preminula je mesec dana nakon
operacije. Zakljuÿak. Negastacijski metastatski horiokar-
cinom komplikovan drugim tipom maligniteta sa ranim ši-
renjem bolesti i slabim odgovorom na hematerapiju ima
lošu prognozu sa letalnim ishodom.
Kljuÿne reÿi:
horiokarcinom; horiokarcinom, negestacijski;
karcinom; dijagnoza; leÿenje lekovima; hirurgija,
digestivni sistem, procedure; hirurgija, ginekološka,
procedure; prognoza; leÿenje, ishod.
Introduction
Gestational trophoblastic neoplasms (GTNs) can appear
as benign GTNs (complete or partial hydatiform mole) as
well as invasive mole, choriocarcinoma or placental site tro-
phoblastic tumor as malignant GTNs. Among GTNs, chorio-
carcinoma is a highly potent malignancy of trophoblastic
origin and usualy represents disturbance of fertilization. Cho-
riocarcinoma is a rare event, highly malignant tumor and in
the majority of instancies its localization is intrauterine and
of gestational origine. Choriocarcinoma usually occurs after
normal pregnancies, after term pregnancies and after molar
pregnancies 
1. It can also occur after nongestational events 
2, 3.
Serum beta human chorionic gonadotropin (HCG) elevation
depends on hormone secretion component of choriocarci-
noma (syncyciotrophoblast) 
4, 5. Extrauterine localization of
choriocarcinoma is rare and can develop on ectopic preg-
nancy. It is believed that some malignant non-gestational
trophoblastic malignancies especially choriocarcinoma can
develop from pluripotent germ cells in the gonads. If non-
gestational choriocarcinoma invades and metastatises early
and rapidly without specific clinical manifestation it may
have a poor prognosis. Diagnosis can be confirmed after
histological and immunohistochemical examinations. This
means that poorly differentiated carcinomas may show focal
area of choriocarcinomatous differentiation 
6, 7.
Case report
A 20-year-old patient presented with abdominal and ret-
roperitoneal malignancy – anaplastic carcinoma (gravida 1,
parity 1). The tumor developed three months after left ad-
nexectomy because of cystic tumor 8 u 7 u 9 cm. CA 125
levels were 16 U/mL (< 35 U/mL ref. value). Immunohisto-
chemical examination was done and tumor cells were identi-
fied as CK7, CK20 and beta HCG positive and diagnosis of
choriocarcinoma was confirmed. The patient was treated in
another country. Two courses of chemotherapy, methotrexate
50 mg/m
2 im on the days 1, 3, 5, 7 + folic acid 30 mg iv on
the days 2, 4, 6, 8 (MTX + FA), were administrated without
checking initial HCG level.
The patient came to our hospital with a history of pelvic
pain and developing abdominal and left retroperitoneal tu-
mor 3 months after left adnexectomy and 2 courses of che-
motherapy. Right adnexectomy was done one year before
this operation and histopathological findings confirmed bor-
derline cystadenoma ovarii.
On admission to hospital the patient had palpable ab-
dominal masses, pelvic and abdominal pain and progressive
anemia. The tumor that developed 3 months after left ad-
nexectomy and 2 courses of chemotherapy because of the
confirmed non-gestational choriocarcinoma spreaded retro-
peritonealy and also in the abdominal cavity. We checked
HCG and it was 38 mlU/L. Tumor marker CA-125 and al-
pha-fetoprotein (AFP) levels were in normal ranges. Trans-
vaginal Doppler ultrasonographic examination was done and
normal uterus without pelvic masses was seen. Hyperecho-
genic masses were suspected on the left lateral and back ret-
roperitoneal and invaded to the left subphrenium (Figure 1).
This was confirmed on computed tomography (CT) scans of
abdomen and pelvis. CT scans of the pelvis showed the nor-
mal uterus without pathological masses and there was a het-
erogenous mass dimenssions 25 u 39 u 37 cm partly in ab-
Fig. 1 – Ultrasonography of abdominal and retroperitoneal
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dominal cavity and mostly invaded left retroperitonealy
(Figure 2). Brain and lung metastases were excluded after X-
ray examination.
Fig. 2 – Computed tomography (CT) scan of an abdominal
and retroperitoneal tumor mass
The patient had progressive anemia with hematocrite
(hct) 29%–19% (reference values 37.0%–51.0%) and hypo-
albuminemia 25–27 g/L (reference values 32–50 g/L). Dur-
ing the first 4 days the patient got 8 blood units and 12 units
of fresh frosen plasma (FFP). Broad spectrum antibiotics
administrated on the second day of hospitalisation when the
patient became febrile (38–39.5°C) with increasing leuko-
cytes (> 12 u 10
9/L) , platelets (> 400 u 10
9/L) and also in-
creasing CRP > 165 mg/L (reference value < 5.0 mg/L).
To prevent multiorganic failure, endotoxic shock or/and
disseminated intravascular coagulation caused by hemor-
rhage and infection in tumor mass we decided to exceede the
tumor mass. Because of the great risk of hemorrhage biopsy
of metastasis is not recommended in patients with metastatic
choriocarcinoma. We decided to do it inspite of the risks, so
we could make the right decision for the final treatment and
to find the source of hemorrhage and suspected developing
infection. Tumor biopsy was done and metastatic choriocar-
cinoma with predominant anaplastic carcinoma was con-
firmed (Figure 3). According to this and also ultrasono-
graphic and CT findings we prepared the patient for radical
tumor excision. Preparation included administrating appro-
priate chemotherapy regimen. Suggested chemotherapy
regimens for choriocarcinoma treatment include the follow-
ing: MAC regimen – metotrexate (MTX) + actinomycin–d +
cyclophosphamid, then EMA/CO – etoposide + metotrexate
+ actinomycin-d + cyclophosphamid + vincristin. Unfortu-
nately, these protocols could not be administrated in Serbia
because actinomycin-d is not registrated.
That means that chemotherapy regimen was modified
and 5 days metotrexate + cyclophosphamid regimen was
administrated before total tumor excision. This therapy
showed to be effective and one week later beta HCG was 2
mlU/L. Because of immunohistochemically confirmed meta-
static focus of choriocarcinoma in predominant anaplastic car-
cinoma and only one positive HCG level of 38 mlU/mL, 5 day
chemotherapy (methotrexate 15 mg IV + cyclophosphamide
300 mg IV) was administrated according to the protocol.
One week after chemotherapy serum HCG was below 5
mlU/mL. During and after chemotherapy the patient got 8
blood units and 9 units of FFP. Broad spectrum antibiotics
continued administrating. The operative treatment was done
in collaboration with vascular surgeon. Rupture of sigmoid
colon and hemorrhage in tumor mass were found. The tumor
had been exceeded in toto (Figure 4). On the day before and
during the operation, 12 doses of blood were transfused and
6 doses of FFP. Immunohistochemical examination excluded
metastases of choriocarcinoma in the exceeded tumor mass.
After chemotherapy and total tumor excision anaplastic car-
cinoma was confirmed with intestinal infiltration and large
fields of necrosis and bleeding. Tumor cells were CK7,
Fig. 3 – Anaplastic carcinoma (histopathologic finding of
tumor biopsy post chemotherapy; HE, u200)
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CK20, beta HCG, PLAP, inhibin and p63 negative. Our pa-
tient had nongestational choriocarcinoma with poor prognosis.
The patient had early and extensive development of anaplastic
carcinoma with choriocarcinoma foci complicated with rup-
tured sigmoid colon, infection and hemorrhage in tumor tissue.
This explains progressive anemia, infection and febrile state.
Nine days after the operation the patient went home recovered
but died one month later becouse had rejected chemotherapy
recommended according to the protocol.
Discussion
Non-gestational choriocarcinoma is a rare trophoblastic
malignancy. If diagnosed on time and treated it can also be
curable. If it does not invade nor metastatize early the prog-
nosis can be better and the treatment more successful. Some-
times it spreads in the abdomen and also retroperitonealy.
Non-gestational choriocarcinoma are followed with signifi-
cantly lower serum beta HCG than in postgestatinal chorio-
carcinoma. That is the reason for poor prognosis in the
time of diagnosis with following complications and letal
outcome 
8, 9. Because of the great risk of hemorrhage bi-
opsy of metastases is not recommended in patients with
metastatic choriocarcinoma. Destruction of local tissue and
organs can be followed with progressive anemia caused by
local hemorrhage in tumor, abdomen or retroperitoneum.
Concommitent infection with high temperature needs antibi-
otic treatment and supportive therapy 
10, 11, 12.
Chest and brain X-ray have to be done to exclude me-
tastases in non-gestational as well as in gestational chorio-
carcinoma. Ultrasonography and CT are also of a great diag-
nostic value 
13. Suggested chemotherapy regimens for cho-
riocarcinoma treatment include following: MAC regimen –
metotrexate (MTX) + actinomycin–d + cyclophosphamid,
then EMA/CO – etoposide + metotrexate + actinomycin-d +
cyclophosphamid + vincristin. Unfortunately, these protocols
could not be administrated in Serbia because actinomycin-d
is not registrated.
In the presented patient the effective chemotherapy
regimen was a modified one: 5 days metotrexate 15 mg iv +
cyclophosphamid 300 mg iv were administrated before the
operation and tumor excission. This therapy showed to be ef-
fective for choriocarcinoma foci in anaplastic carcinoma and
one week later beta human chorionic gonadotropin was 2
mlU/L. Prognosis of non-gestational metastatic choriocarci-
noma depends on the diagnosis as well as on treatment re-
sponse. Delayed diagnosis and low responsiveness to che-
motherapy and early extensive spread of disease mean poor
prognosis and lead to letal outcome.
Conclusion
Non-gestational metastatic choriocarcinoma compli-
cated with another type of malignancy with early spread of
the disease and low responsiveness to chemotherapy has
poor prognosis and leads to lethal outcome.
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